Myeloma protein: Difference between revisions
Varun Kumar (talk | contribs) No edit summary |
No edit summary |
||
Line 14: | Line 14: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} |
Latest revision as of 17:40, 26 August 2015
WikiDoc Resources for Myeloma protein |
Articles |
---|
Most recent articles on Myeloma protein Most cited articles on Myeloma protein |
Media |
Powerpoint slides on Myeloma protein |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Myeloma protein at Clinical Trials.gov Trial results on Myeloma protein Clinical Trials on Myeloma protein at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Myeloma protein NICE Guidance on Myeloma protein
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Myeloma protein Discussion groups on Myeloma protein Patient Handouts on Myeloma protein Directions to Hospitals Treating Myeloma protein Risk calculators and risk factors for Myeloma protein
|
Healthcare Provider Resources |
Causes & Risk Factors for Myeloma protein |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Myeloma Protein is usually a monoclonal antibody or immunoglobulin fragment that is produced by malignant myeloma cells, or plasma cells.
Other terms for this protein is M-protein, spike protein,or paraprotein. This proliferation of the myeloma protein has several deleterious effects on the body, including impaired immune function, abnormally high viscosity ("thickness") of the blood, and kidney damage.[1]